United Therapeutics Won Its Patent War and Liquidia Collapsed

A court ruling materially boosted one pulmonary-hypertension drugmaker while placing its rival under significant pressure, with Yutrepia at the center of the dispute. The legal outcome remains unresolved, leaving both companies exposed to further litigation-driven volatility and potentially significant changes in their competitive positions.